{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T02:41:33Z","timestamp":1788057693015,"version":"build-2784847793"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T00:00:00Z","timestamp":1717372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82173499"],"award-info":[{"award-number":["82173499"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objective<\/jats:title>\n                <jats:p>High low-density-lipoprotein (LDL) cholesterol has been associated with an increased risk of coronary artery diseases (CAD) including acute myocardial infarction (AMI). However, whether lipids lowering drug treatment is causally associated with decreased risk of AMI remains largely unknown. We used Mendelian randomization (MR) to evaluate the influence of genetic variation affecting the function of lipid-lowering drug targets on AMI.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Single-nucleotide polymorphisms (SNPs) associated with lipids as instruments were extracted from the Global Lipids Genetics Consortium (GLGC). The genome-wide association study (GWAS) data for AMI were obtained from UK Biobank. Two sample MR analysis was used to study the associations between high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, and triglycerides (TG) with AMI (<jats:italic>n<\/jats:italic>\u2009=\u20093,927). Genetic variants associated with LDL cholesterol at or near drug target gene were used to mimic drug effects on the AMI events in drug target MR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Genetically predicted higher LDL-C (per one SD increase in LDL-C of 38.67\u00a0mg\/dL, OR 1.006, 95% CI 1.004\u20131.007) and TG (per one SD increase in TG of 90.72\u00a0mg\/dL, 1.004, 1.002\u20131.006) was associated with increased risk of AMI, but decreased risk for higher HDL-C (per one SD increase in HDL-C of 15.51\u00a0mg\/dL, 0.997, 0.995\u20130.999) in univariable MR. Association remained significant for LDL-C, but attenuated toward the null for HDL-C and TG in multivariable MR. Genetically proxied lower LDL-C with genetic variants at or near the <jats:italic>PCSK9<\/jats:italic> region (drug target of evolocumab) and <jats:italic>NPC1L1<\/jats:italic> (drug target of ezetimibe) were associated with decreased risk of AMI (0.997, 0.994\u20130.999 and 0.986, 0.975\u20130.998, respectively), whereas genetic variants at <jats:italic>HMGCR<\/jats:italic> region (drug target of statin) showed marginal association with AMI (0.995, 0.990-1.000). After excluding drug target-related SNPs, LDL-C related SNPs outside the drug target region remained a causal effect on AMI (0.994, 0.993\u20130.996).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The findings suggest that genetically predicted LDL-C may play a predominant role in the development of AMI. The drug MR results imply that ezetimibe and evolocumab may decrease the risk of AMI due to their LDL-C lowering effect, and there are other non-drug related lipid lowering pathways that may be causally linked to AMI.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12944-024-02133-w","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T05:02:03Z","timestamp":1717390923000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effects of genetically proxied lipid-lowering drugs on acute myocardial infarction: a drug-target mendelian randomization study"],"prefix":"10.1186","volume":"23","author":[{"given":"Wendi","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueying","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhuang","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zimin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxiu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ninghao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinzhu","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonghua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,3]]},"reference":[{"issue":"2","key":"2133_CR1","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/j.ijcard.2014.04.096","volume":"174","author":"AN Nowbar","year":"2014","unstructured":"Nowbar AN, et al. 2014 global geographic analysis of mortality from ischaemic heart disease by country, age and income: statistics from World Health Organisation and United Nations. Int J Cardiol. 2014;174(2):293\u20138.","journal-title":"Int J Cardiol"},{"issue":"9","key":"2133_CR2","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMoa1311890","volume":"371","author":"S Yusuf","year":"2014","unstructured":"Yusuf S, et al. Cardiovascular risk and events in 17 Low-, Middle-, and high-income countries. N Engl J Med. 2014;371(9):818\u201327.","journal-title":"N Engl J Med"},{"key":"2133_CR3","unstructured":"Mechanic OJ, Gavin M, Grossman SA. Acute Myocardial Infarction, in StatPearls. 2022, StatPearls Publishing Copyright \u00a9 2022, StatPearls Publishing LLC.: Treasure Island (FL)."},{"issue":"18","key":"2133_CR4","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1001\/jama.2009.1619","volume":"302","author":"E Di Angelantonio","year":"2009","unstructured":"Di Angelantonio E, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302(18):1993\u20132000.","journal-title":"JAMA"},{"issue":"9753","key":"2133_CR5","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","volume":"376","author":"C Baigent","year":"2010","unstructured":"Baigent C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670\u201381.","journal-title":"Lancet"},{"issue":"6","key":"2133_CR6","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jacc.2017.12.006","volume":"71","author":"MV Holmes","year":"2018","unstructured":"Holmes MV, et al. Lipids, lipoproteins, and metabolites and risk of myocardial infarction and stroke. J Am Coll Cardiol. 2018;71(6):620\u201332.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2133_CR7","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1056\/NEJMoa1110874","volume":"365","author":"SJ Nicholls","year":"2011","unstructured":"Nicholls SJ, et al. Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med. 2011;365(22):2078\u201387.","journal-title":"N Engl J Med"},{"issue":"12","key":"2133_CR8","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1001\/jama.2016.13985","volume":"316","author":"MG Silverman","year":"2016","unstructured":"Silverman MG, et al. Association between lowering LDL-C and Cardiovascular Risk Reduction among different therapeutic interventions: a systematic review and Meta-analysis. JAMA. 2016;316(12):1289\u201397.","journal-title":"JAMA"},{"issue":"7404","key":"2133_CR9","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1136\/bmj.326.7404.1423","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326(7404):1423.","journal-title":"BMJ"},{"issue":"15","key":"2133_CR10","doi-asserted-by":"publisher","first-page":"1552","DOI":"10.1016\/j.jacc.2015.02.020","volume":"65","author":"BA Ference","year":"2015","unstructured":"Ference BA, et al. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. J Am Coll Cardiol. 2015;65(15):1552\u201361.","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"2133_CR11","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1056\/NEJMoa1604304","volume":"375","author":"BA Ference","year":"2016","unstructured":"Ference BA, et al. Variation in PCSK9 and HMGCR and risk of Cardiovascular Disease and Diabetes. N Engl J Med. 2016;375(22):2144\u201353.","journal-title":"N Engl J Med"},{"issue":"2","key":"2133_CR12","doi-asserted-by":"publisher","first-page":"e1003898","DOI":"10.1371\/journal.pmed.1003898","volume":"19","author":"D Gill","year":"2022","unstructured":"Gill D, Burgess S. The evolution of mendelian randomization for investigating drug effects. PLoS Med. 2022;19(2):e1003898.","journal-title":"PLoS Med"},{"key":"2133_CR13","doi-asserted-by":"publisher","first-page":"16","DOI":"10.12688\/wellcomeopenres.16544.1","volume":"6","author":"D Gill","year":"2021","unstructured":"Gill D, et al. Mendelian randomization for studying the effects of perturbing drug targets. Wellcome Open Res. 2021;6:16.","journal-title":"Wellcome Open Res"},{"issue":"4","key":"2133_CR14","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/aje\/kwu283","volume":"181","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson SG. Multivariable mendelian randomization: the use of pleiotropic genetic variants to estimate causal effects. Am J Epidemiol. 2015;181(4):251\u201360.","journal-title":"Am J Epidemiol"},{"issue":"3","key":"2133_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1093\/ije\/dyy262","volume":"48","author":"E Sanderson","year":"2019","unstructured":"Sanderson E, et al. An examination of multivariable mendelian randomization in the single-sample and two-sample summary data settings. Int J Epidemiol. 2019;48(3):713\u201327.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"2133_CR16","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ng.2797","volume":"45","author":"CJ Willer","year":"2013","unstructured":"Willer CJ, et al. Discovery and refinement of loci associated with lipid levels. Nat Genet. 2013;45(11):1274\u201383.","journal-title":"Nat Genet"},{"issue":"22","key":"2133_CR17","doi-asserted-by":"publisher","first-page":"4851","DOI":"10.1093\/bioinformatics\/btz469","volume":"35","author":"MA Kamat","year":"2019","unstructured":"Kamat MA, et al. PhenoScanner V2: an expanded tool for searching human genotype-phenotype associations. Bioinformatics. 2019;35(22):4851\u20133.","journal-title":"Bioinformatics"},{"issue":"11","key":"2133_CR18","doi-asserted-by":"publisher","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","volume":"13","author":"G Hemani","year":"2017","unstructured":"Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between imprecisely measured traits using GWAS summary data. PLoS Genet. 2017;13(11):e1007081.","journal-title":"PLoS Genet"},{"issue":"7","key":"2133_CR19","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1001\/jama.2020.0150","volume":"323","author":"J Yarmolinsky","year":"2020","unstructured":"Yarmolinsky J, et al. Association between genetically proxied inhibition of HMG-CoA reductase and epithelial ovarian Cancer. JAMA. 2020;323(7):646\u201355.","journal-title":"JAMA"},{"key":"2133_CR20","doi-asserted-by":"publisher","DOI":"10.1201\/b18084","volume-title":"Mendelian randomization: methods for using genetic variants in causal estimation","author":"S Burgess","year":"2015","unstructured":"Burgess S, Thompson S. Mendelian randomization: methods for using genetic variants in causal estimation. Boca Raton, FL 33487\u2009\u2013\u20092742: Taylor & Francis Group, LLC; 2015. 6000 Broken Sound Parkway NW, Suite 300."},{"issue":"7","key":"2133_CR21","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1002\/gepi.21758","volume":"37","author":"S Burgess","year":"2013","unstructured":"Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol. 2013;37(7):658\u201365.","journal-title":"Genet Epidemiol"},{"issue":"11","key":"2133_CR22","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1002\/sim.7221","volume":"36","author":"J Bowden","year":"2017","unstructured":"Bowden J, et al. A framework for the investigation of pleiotropy in two-sample summary data mendelian randomization. Stat Med. 2017;36(11):1783\u2013802.","journal-title":"Stat Med"},{"issue":"2","key":"2133_CR23","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1093\/ije\/dyv080","volume":"44","author":"J Bowden","year":"2015","unstructured":"Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol. 2015;44(2):512\u201325.","journal-title":"Int J Epidemiol"},{"issue":"4","key":"2133_CR24","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1002\/gepi.21965","volume":"40","author":"J Bowden","year":"2016","unstructured":"Bowden J, et al. Consistent estimation in mendelian randomization with some Invalid instruments using a weighted median estimator. Genet Epidemiol. 2016;40(4):304\u201314.","journal-title":"Genet Epidemiol"},{"issue":"21","key":"2133_CR25","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1002\/sim.6522","volume":"34","author":"MF Greco","year":"2015","unstructured":"Greco MF, et al. Detecting pleiotropy in mendelian randomisation studies with summary data and a continuous outcome. Stat Med. 2015;34(21):2926\u201340.","journal-title":"Stat Med"},{"issue":"5","key":"2133_CR26","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41588-018-0099-7","volume":"50","author":"M Verbanck","year":"2018","unstructured":"Verbanck M, et al. Detection of widespread horizontal pleiotropy in causal relationships inferred from mendelian randomization between complex traits and diseases. Nat Genet. 2018;50(5):693\u20138.","journal-title":"Nat Genet"},{"issue":"9","key":"2133_CR27","doi-asserted-by":"publisher","first-page":"e0222362","DOI":"10.1371\/journal.pone.0222362","volume":"14","author":"JMB Rees","year":"2019","unstructured":"Rees JMB, et al. Robust methods in mendelian randomization via penalization of heterogeneous causal estimates. PLoS ONE. 2019;14(9):e0222362.","journal-title":"PLoS ONE"},{"issue":"4","key":"2133_CR28","doi-asserted-by":"publisher","first-page":"721","DOI":"10.3945\/ajcn.115.113548","volume":"102","author":"DL Streiner","year":"2015","unstructured":"Streiner DL. Best (but oft-forgotten) practices: the multiple problems of multiplicity-whether and how to correct for many statistical tests. Am J Clin Nutr. 2015;102(4):721\u20138.","journal-title":"Am J Clin Nutr"},{"key":"2133_CR29","doi-asserted-by":"crossref","unstructured":"Hemani G et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife, 2018. 7.","DOI":"10.7554\/eLife.34408"},{"issue":"6","key":"2133_CR30","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","volume":"46","author":"OO Yavorska","year":"2017","unstructured":"Yavorska OO, Burgess S. MendelianRandomization: an R package for performing mendelian randomization analyses using summarized data. Int J Epidemiol. 2017;46(6):1734\u20139.","journal-title":"Int J Epidemiol"},{"issue":"20","key":"2133_CR31","doi-asserted-by":"publisher","first-page":"3207","DOI":"10.1093\/bioinformatics\/btw373","volume":"32","author":"JR Staley","year":"2016","unstructured":"Staley JR, et al. PhenoScanner: a database of human genotype-phenotype associations. Bioinformatics. 2016;32(20):3207\u20139.","journal-title":"Bioinformatics"},{"key":"2133_CR32","doi-asserted-by":"crossref","unstructured":"Collaboration* TERF. Major lipids, apolipoproteins, and risk of Vascular Disease. JAMA. 2009;302(18):1993\u20132000.","DOI":"10.1001\/jama.2009.1619"},{"key":"2133_CR33","doi-asserted-by":"crossref","unstructured":"Richardson TG et al. Evaluating the relationship between circulating lipoprotein lipids and apolipoproteins with risk of coronary heart disease: A multivariable Mendelian randomisation analysisPLoS Med, 2020. 17(3): p. e1003062.","DOI":"10.1371\/journal.pmed.1003062"},{"issue":"9841","key":"2133_CR34","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(12)60312-2","volume":"380","author":"BF Voight","year":"2012","unstructured":"Voight BF, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet. 2012;380(9841):572\u201380.","journal-title":"Lancet"},{"issue":"2","key":"2133_CR35","doi-asserted-by":"publisher","first-page":"E248","DOI":"10.1210\/jc.2011-1846","volume":"97","author":"CL Haase","year":"2012","unstructured":"Haase CL, et al. LCAT, HDL cholesterol and ischemic cardiovascular disease: a mendelian randomization study of HDL cholesterol in 54,500 individuals. J Clin Endocrinol Metab. 2012;97(2):E248\u201356.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2133_CR36","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/ng.2795","volume":"45","author":"R Do","year":"2013","unstructured":"Do R, et al. Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013;45(11):1345\u201352.","journal-title":"Nat Genet"},{"issue":"4","key":"2133_CR37","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1001\/jama.2018.20045","volume":"321","author":"BA Ference","year":"2019","unstructured":"Ference BA, et al. Association of Triglyceride-Lowering LPL variants and LDL-C-Lowering LDLR variants with risk of Coronary Heart Disease. JAMA. 2019;321(4):364\u201373.","journal-title":"JAMA"},{"issue":"10","key":"2133_CR38","first-page":"pCd011748","volume":"10","author":"AF Schmidt","year":"2020","unstructured":"Schmidt AF, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2020;10(10):pCd011748.","journal-title":"Cochrane Database Syst Rev"},{"issue":"11","key":"2133_CR39","first-page":"pCd012502","volume":"11","author":"S Zhan","year":"2018","unstructured":"Zhan S, et al. Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev. 2018;11(11):pCd012502.","journal-title":"Cochrane Database Syst Rev"},{"key":"2133_CR40","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.ijcard.2015.08.103","volume":"201","author":"G Savarese","year":"2015","unstructured":"Savarese G, et al. Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol. 2015;201:247\u201352.","journal-title":"Int J Cardiol"},{"key":"2133_CR41","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1146\/annurev.pharmtox.45.120403.095748","volume":"45","author":"JK Liao","year":"2005","unstructured":"Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol. 2005;45:89\u2013118.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2133_CR42","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCRESAHA.116.308537","volume":"120","author":"A Oesterle","year":"2017","unstructured":"Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the Cardiovascular System. Circ Res. 2017;120(1):229\u201343.","journal-title":"Circ Res"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02133-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-024-02133-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-024-02133-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T05:03:20Z","timestamp":1717391000000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-024-02133-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,3]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2133"],"URL":"https:\/\/doi.org\/10.1186\/s12944-024-02133-w","relation":{},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,3]]},"assertion":[{"value":"20 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research has been conducted using the UK Biobank Resource under Application Number 44430. The National Information Governance Board has approved the UK Biobank study for Health and Social Care in England and Wales, the Community Health Index Advisory Group in Scotland, and the Northwest Multicenter Research Ethics Committee. This study was also approved by the Ethical Committee of Peking University (Beijing, China).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"163"}}